The Shanghai-based company, which operates across Asia, Europe, and North America, confirmed the payout for both A-share and H-share holders. This distribution follows the firm's inaugural interim dividend last year, reflecting a consistent policy of channeling financial gains back to investors while maintaining its end-to-end R&D and manufacturing services.
Shareholders are directed to the company’s official regulatory filings for specific payment details regarding the 2026 mid-year distribution. As a major player in the global life sciences sector, WuXi AppTec continues to leverage its integrated platform to support development projects in over 30 countries, aiming to accelerate the delivery of breakthrough treatments to patients worldwide.
Comments (0)
No comments yet. Be the first!